<?xml version="1.0" encoding="UTF-8"?>
<p>Several therapeutic molecules (Table 
 <xref rid="rmv2143-tbl-0002" ref-type="table">2</xref>), identified in antiviral screenings performed in infected cells, target the renin/angiotensin pathway.
 <xref rid="rmv2143-bib-0039" ref-type="ref">
  <sup>39</sup>
 </xref>, 
 <xref rid="rmv2143-bib-0100" ref-type="ref">
  <sup>100</sup>
 </xref>, 
 <xref rid="rmv2143-bib-0101" ref-type="ref">
  <sup>101</sup>
 </xref> The MoA of these class of inhibitors is speculative. Interestingly, ACE2 belongs to this pathway. An in vivo study has shown that inhibition of the renin/angiotensin pathway upregulates of ACE2 which can increase susceptibility to SARS‐CoV‐2 infection.
 <xref rid="rmv2143-bib-0102" ref-type="ref">
  <sup>102</sup>
 </xref> More recently, it has been shown that treatment target this pathway is not associated with higher severity of COVID19
 <xref rid="rmv2143-bib-0103" ref-type="ref">
  <sup>103</sup>
 </xref> Additional work is needed to understand how these compounds inhibit the virus before planning clinical trials.
</p>
